M&As in pharma and those troublesome human factors

In a special feature for Pharma Times, Harry Malcolm, Principal Consultant at Rubica, delves into the world of mergers and acquisitions (M&A) and candidly:

• Discusses the common challenges leading to the frequent failure of M&A endeavors in pharma,
• Sheds light on the often overlooked “people aspect” of M&As and the far-reaching implications it can have,
• Offers insights from senior pharma leaders at AstraZeneca, CSL Vifor, and Sobi on the essential components for effectively integrating people in an M&A process
• Shares practical ideas on how to ensure the ‘people aspect’ of an M&A isn’t neglected

You can take a read of the full article by clicking here.